Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cellular Biomedicine approved for listing on NASDAQ Capital Market


Monday, 16 Jun 2014 08:00am EDT 

Cellular Biomedicine Group Inc:Says its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "CBMG" on June 18.Common stock will continue to trade as "CBMG" on the OTCQB until the market closes on June 17. 

Company Quote

12.9
-0.29 -2.20%
26 Dec 2014